Alternative Data for Arrowhead Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 138 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 30,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 42 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,379 | Sign up | Sign up | Sign up |
| X Followers | 3,819 | Sign up | Sign up | Sign up |
| X Mentions | 47 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 64 | Sign up | Sign up | Sign up |
| Linkedin Employees | 748 | Sign up | Sign up | Sign up |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Price | $77.88 |
| Target Price | Sign up |
| Volume | 2,700,204 |
| Market Cap | $11B |
| Year Range | $27.17 - $79.14 |
| Dividend Yield | 0% |
| PE Ratio | 45.43 |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline PotentialMay 2 - Yahoo Entertainment |
|
 |
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 EventsFebruary 23 - Yahoo |
 |
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout OpportunityFebruary 19 - ChartMill |
|
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely LimitedFebruary 17 - Yahoo |
|
ARWR: Strong Start for REDEMPLO Commercialization…February 10 - Yahoo |
|
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder ReturnFebruary 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 74M | 0 | 0 | -133M | -141M | |
| Q4 '25 | 264M | 6.4M | 264M | 31M | 57M | 0.220 |
| Q3 '25 | 256M | 6.4M | 256M | -24M | 64M | -0.110 |
| Q2 '25 | 28M | 6.2M | 28M | -175M | -148M | -1.260 |
| Q1 '25 | 543M | 6.1M | 537M | 370M | 397M | 2.750 |
Insider Transactions View All
| Hamilton James C filed to sell 226,958 shares at $75. April 24 '26 |
| Apel Daniel Joseph filed to sell 171,635 shares at $70.5. April 24 '26 |
| Apel Daniel Joseph filed to sell 172,792 shares at $70.1. April 24 '26 |
| Apel Daniel Joseph filed to sell 162,905 shares at $71.9. April 24 '26 |
| Hamilton James C filed to sell 236,958 shares at $64.2. March 9 '26 |
Similar companies
Read more about Arrowhead Pharmaceuticals (ARWR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Arrowhead Pharmaceuticals
The Market Cap of Arrowhead Pharmaceuticals is $11B.
As of today, Arrowhead Pharmaceuticals' PE (Price to Earnings) ratio is 45.43.
Currently, the price of one share of Arrowhead Pharmaceuticals stock is $77.88.
The ARWR stock price chart above provides a comprehensive visual representation of Arrowhead Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arrowhead Pharmaceuticals shares. Our platform offers an up-to-date ARWR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Arrowhead Pharmaceuticals (ARWR) does not offer dividends to its shareholders. Investors interested in Arrowhead Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Arrowhead Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
